Global Pregabalin Market Size By Type (Epilepsy, Neuropathic Pain), By Application (Research Institutes, Pharmaceutical Companies), By Region, And Segment Forecasts, 2023 to 2032

The Global Pregabalin Market was valued at USD 5.1 billion in 2023 and is projected to reach USD 8.4 billion by 2031, growing at a CAGR of 6.4% during the forecast period from 2023 to 2031. Pregabalin, a widely used anticonvulsant and neuropathic pain reliever, is primarily prescribed for conditions such as epilepsy, fibromyalgia, generalized anxiety disorder, and neuropathic pain. The market is experiencing robust growth due to the rising prevalence of chronic pain disorders, expanding geriatric population, and increasing awareness and diagnosis of neurological conditions. Additionally, the growing number of generic manufacturers after patent expiries is expanding market accessibility, especially in emerging economies.

Drivers:

1. Rising Prevalence of Neuropathic Disorders:

Increasing global incidences of conditions like diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia are propelling the demand for pregabalin as a first-line therapy for neuropathic pain management.

2. Expanding Geriatric Population:

Older adults are more prone to chronic pain and neurological disorders, thereby contributing to the sustained demand for pregabalin. With the global elderly population on the rise, the long-term market prospects remain strong.

3. Availability of Generics Post Patent Expiry:

The expiration of Pfizer’s Lyrica (brand-name pregabalin) patent has opened the market to a broad range of cost-effective generic alternatives, significantly increasing product accessibility in both developed and developing countries.

Restraints:

1. Potential for Abuse and Regulatory Challenges:

Pregabalin has shown potential for misuse and dependency, leading several countries to impose strict regulatory controls that may hinder market growth and accessibility.

2. Side Effects and Contraindications:

Concerns around side effects such as dizziness, fatigue, and weight gain, along with limited efficacy in certain patient groups, pose a restraint to broader adoption.

Opportunity:

1. Expansion into Emerging Markets:

Improving healthcare infrastructure and growing awareness in countries such as India, Brazil, and Indonesia offer untapped growth potential. Strategic collaborations and pricing strategies can help penetrate these cost-sensitive markets.

2. Rising Application in Mental Health Treatments:

Recent studies and off-label uses in psychiatric indications like anxiety disorders are opening new avenues for market expansion. The growing mental health awareness globally supports this emerging application trend.

Market by System Type Insights:

Based on formulation, the oral capsule segment held the largest market share in 2023 due to ease of administration and widespread preference among both healthcare providers and patients. However, the extended-release formulations segment is projected to witness the fastest growth during the forecast period, owing to improved compliance and reduced dosing frequency.

Market by End-Use Insights:

By end-use, the hospital pharmacies segment led the market in 2023, primarily due to a higher rate of prescriptions for chronic pain and neurological issues through inpatient care. The retail pharmacy segment is expected to grow substantially due to the growing trend of outpatient care and availability of over-the-counter (OTC) generics in certain markets.

Market by Regional Insights:

North America dominated the global pregabalin market in 2023, supported by high diagnosis rates, developed healthcare infrastructure, and wide generic availability. Asia-Pacific is projected to grow at the fastest CAGR through 2031, driven by a burgeoning population, increasing healthcare expenditure, and rising incidences of diabetes and neuropathic conditions.

Competitive Scenario:

Key players in the global pregabalin market include Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Lupin Ltd., Sun Pharmaceutical Industries Ltd., Zydus Lifesciences, Cipla Ltd., Torrent Pharmaceuticals, and Dr. Reddy's Laboratories. These companies are focusing on expanding generic portfolios, entering strategic partnerships, and launching advanced formulations to gain a competitive edge.

Scope of Work – Global Pregabalin Market

Key Market Developments:

2023: Lupin Ltd. launched its generic version of Lyrica in multiple European markets, improving affordability and accessibility.

2024: Pfizer introduced an extended-release formulation targeting enhanced patient adherence for chronic pain management.

2025: Teva Pharmaceuticals entered into a strategic collaboration with a Southeast Asian distributor to strengthen its regional footprint for pregabalin generics.

FAQs:

1) What is the current market size of the Global Pregabalin Market?

The market size of the Global Pregabalin Market was USD 5.1 billion in 2023.

2) What is the major growth driver of the Global Pregabalin Market?

The major growth driver is the rising prevalence of neuropathic disorders and the expansion of generics post patent expiry.

3) Which is the largest region during the forecast period in the Global Pregabalin Market?

North America is currently the largest region, though Asia-Pacific is expected to experience the fastest growth.

4) Which segment accounted for the largest market share in the Global Pregabalin Market?

The oral capsule formulation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Pregabalin Market?

Key players include Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Sun Pharma, Lupin Ltd., and Cipla Ltd.